Loratadine

Introduction Overview

Generic Name

loratadine

Brand Name

Alavert, Claritin, Claritin Reditab, ohm Allergy Relief, Tavist ND, Wal-itin

Dosage Form

oral capsule (10 mg), oral syrup (5 mg/5 mL), oral tablet (10 mg), oral tablet chewable (5 mg), oral tablet disintegrating (10 mg; 5 mg)

Drug Class

Antihistamines

Pharmacokinetics

Absorption:
Loratadine, when administered orally, is rapidly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are typically reached within 1 to 1.5 hours post-dose. The drug is well absorbed, and food does not significantly affect its bioavailability. The rapid onset of absorption allows loratadine to begin exerting its antihistaminic effects usually within 20 minutes of administration, with maximum clinical effects observed in about 1 to 3 hours. The bioavailability is generally high, permitting convenient once-daily dosing for sustained effect.

Distribution:
Once absorbed, loratadine is extensively distributed throughout the body. It is highly protein-bound, primarily to albumin, approximately 97-99%, which helps maintain stable plasma concentrations and limits the free drug fraction. The volume of distribution is moderate, indicating adequate tissue penetration. Loratadine crosses the blood-brain barrier minimally, which accounts for its low sedative effects compared to first-generation antihistamines. The preferential peripheral H1 receptor blockade with limited central nervous system penetration accounts for its favorable safety profile.

Metabolism:
Loratadine undergoes extensive hepatic metabolism primarily via the cytochrome P450 system, especially CYP3A4 and to a lesser extent CYP2D6. It is converted predominantly to an active metabolite, desloratadine (also an effective H1 receptor antagonist), which contributes substantially to the drug's antihistaminic activity and prolonged duration. The metabolic pathways involve oxidative N-demethylation and hydroxylation. Genetic polymorphisms affecting these cytochrome P450 enzymes can influence plasma levels but generally do not necessitate dosage adjustments in routine clinical practice.

Elimination:
Elimination of loratadine and its metabolites occurs mainly through biliary and renal excretion. Approximately 40% of the drug is excreted in the urine primarily as metabolites, and the remainder is eliminated via feces. The elimination half-life of loratadine is about 8 hours, whereas the active metabolite has a half-life of approximately 27 hours, supporting once-daily dosing. Loratadine’s clearance may be reduced in patients with hepatic or renal impairment, requiring caution but typically no formal dose adjustment unless severe dysfunction is present.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 10 mg
- Oral syrup: 5 mg/5 mL
- Oral tablet (regular): 10 mg
- Oral chewable tablet: 5 mg
- Oral disintegrating tablets (ODT): 10 mg and 5 mg

Dosages for Adults and Adolescents:
- Allergic rhinitis and urticaria: 10 mg once daily orally
- Maximum daily dose: 10 mg
- Pediatric dosing (6 years and older): same as adult dose (10 mg once daily)

Specific Patient Populations:
- Pediatric patients 2 to 5 years of age: 5 mg once daily orally, maximum 5 mg/day
- Children younger than 2 years: use not recommended without medical supervision
- Patients with hepatic or renal impairment: caution advised; clinical monitoring recommended
- Pregnancy and breastfeeding: use only if clearly needed after medical consultation

Clinical Guidelines:
Loratadine is designed for once-daily dosing due to its long duration of action and active metabolite's prolonged half-life. It is generally well tolerated and convenient for chronic allergy management. The disintegrating tablets provide an option for patients with difficulty swallowing and contain phenylalanine, relevant for patients with phenylketonuria (PKU). The chewable tablets must be chewed before ingestion. Liquid formulations allow accurate dosing in young children or those unable to swallow tablets.

Mechanism Of Action

Loratadine functions as a selective antagonist of peripheral histamine H1 receptors. Histamine, a biogenic amine stored in mast cells and basophils, mediates many allergic symptoms by binding to H1 receptors on target cells, leading to vasodilation, increased vascular permeability, and sensory nerve stimulation causing itching and sneezing. By competitively binding to these H1 receptors without activating them, loratadine inhibits histamine-mediated responses, thereby reducing classical allergy symptoms such as rhinorrhea, sneezing, and pruritus.

At the molecular level, loratadine has high affinity for peripheral H1 receptors but negligible penetration into the central nervous system due to low lipid solubility and P-glycoprotein efflux at the blood-brain barrier. This selectivity means loratadine minimizes sedation and cognitive impairment typically seen with earlier first-generation antihistamines, enhancing its safety profile for daily use.

The active metabolite desloratadine also possesses potent H1 receptor antagonism, prolonging antihistaminic effects beyond the parent drug's presence. This metabolite contributes significantly to the sustained relief of allergy symptoms, enabling once-daily dosing. Clinical studies confirm that loratadine’s receptor blockade reduces vasodilation, capillary permeability, and sensory nerve activation, culminating in decreased nasal congestion, ocular irritation, and skin manifestations.

Compared to other second-generation antihistamines such as cetirizine or fexofenadine, loratadine offers a balance of efficacy and minimal sedation, making it a preferred choice in patients requiring symptom control without compromising alertness. Ongoing research reaffirms its non-sedating properties and validates its role in chronic allergic rhinitis and urticaria management as supported by clinical trial evidence.

Pharmacological Actions

Selective peripheral histamine H1 receptor antagonism reducing allergic inflammation
Inhibition of histamine-induced vasodilation and capillary permeability
Suppression of sensory nerve stimulation leading to decreased itching and sneezing
Active metabolite desloratadine extends duration of action and enhances efficacy
Minimal penetration of the blood-brain barrier resulting in low sedation risk
Rapid onset of action with symptom relief beginning within 20 minutes of dosing
Once-daily dosing due to long elimination half-life
Effective in controlling symptoms of allergic rhinitis such as sneezing and rhinorrhea
Reduction of urticaria symptoms including hives and pruritus
Good safety profile with low incidence of anticholinergic side effects
Limited central nervous system depressant effects compared to first-generation antihistamines
Compatibility with various formulations including oral tablets, syrup, and disintegrating tablets

Therapeutic Or Clinical Uses

Management of seasonal allergic rhinitis (hay fever) symptoms such as sneezing, runny nose, and itchy or watery eyes
Treatment of perennial allergic rhinitis with nasal and ocular symptoms
Relief of urticaria including chronic hives characterized by itching and rash
Alleviation of skin-related allergic manifestations such as itching and rash
Symptomatic treatment of allergic conditions mediated by histamine release
Adjunctive therapy in patients requiring non-sedating antihistamines for daily allergy symptom control
Use in pediatric patients aged 2 years and older for allergic conditions (dosage adjusted by age)
Alternative to sedating antihistamines in patients who require maintaining alertness
Over-the-counter use for temporary relief of common cold or allergy symptoms
Prevention of histamine-mediated symptoms in allergic reactions
Supportive treatment in managing pruritus associated with allergic skin conditions
Off-label use includes management of physical urticaria and chronic idiopathic urticaria
Use in conjunction with other therapies for comprehensive allergy management

Side Or Adverse Effects

Headache, reported as the most common adverse effect
Mild drowsiness or fatigue in some individuals despite low sedative potential
Dry mouth and throat discomfort
Gastrointestinal disturbances including nausea and abdominal pain
Feeling nervous, agitation, or hyperactivity especially in pediatric population
Occasional dizziness or light-headedness
Rare cases of allergic reactions such as rash or swelling
Palpitations or tachycardia reported rarely
Potential for insomnia or difficulty sleeping
Throat irritation with oral disintegrating tablets
Uncommon reports of tremors or restlessness
Hypersensitivity reactions in patients with known allergy to loratadine or related compounds
No significant anticholinergic side effects such as dry eyes or blurred vision observed
Low incidence of sedation allows safe use in activities requiring alertness
Rare idiosyncratic adverse reactions requiring medical attention

Precautions

Avoid use in patients with known hypersensitivity to loratadine or desloratadine
Use cautiously in patients with severe liver or kidney impairment due to altered metabolism and excretion
Phenylalanine content in some chewable and disintegrating tablets necessitates caution in patients with phenylketonuria (PKU)
Consult healthcare provider before use during pregnancy or breastfeeding to assess risk-benefit
Not recommended for use in children under 2 years old without medical supervision
Avoid concomitant use with other sedating medications until individual response is known
Monitor for signs of allergic reaction during initial therapy
Caution advised in patients with cardiovascular disease, monitor for palpitations
Use appropriate measuring devices when administering syrup formulations to accurately dose pediatric patients
Discontinue and seek medical advice if symptoms worsen or new symptoms occur
Avoid exceeding recommended doses to prevent potential toxicity
Consider potential drug interactions before starting additional therapies
Inform healthcare providers about all current medications to avoid adverse effects
Use disintegrating tablets as directed to avoid incorrect administration
Store medication properly to maintain stability and efficacy

Warnings

Do not use if allergic to loratadine or its active metabolite desloratadine
Use under medical supervision in patients with liver or kidney disease
Some dosage forms contain phenylalanine; avoid in phenylketonuria (PKU) patients
Avoid double dosing; do not exceed one dose within a 24-hour period
Seek emergency help for signs of severe allergic reactions such as swelling of face, lips, tongue, or difficulty breathing
Potential for cardiac arrhythmias including fast or irregular heart rate, though rare
Stop use and consult physician if severe headache or lightheadedness occurs
Use cautiously in young children as overdose or misuse of cold medications can be fatal
Avoid use with drugs known to prolong QT interval unless closely monitored
Not established as safe or effective in children below 2 years without medical advice
May cause mild drowsiness; use caution when driving or operating machinery
Ensure proper diagnosis before use as symptoms resembling allergies could be due to other serious conditions
Do not share medication with others; intended only for prescribed patient
Store out of reach of children to prevent accidental overdose
Overdose may manifest with tachycardia, drowsiness, and headache requiring emergency intervention

Contraindication

Hypersensitivity to loratadine or any ingredient in the formulation
Known allergy to desloratadine or other structurally related antihistamines
Use in children under 2 years of age unless specifically prescribed by a healthcare provider
Patients with phenylketonuria should avoid chewable or disintegrating tablets containing phenylalanine
Use contraindicated in patients with previous severe allergic reactions to the drug
Patients with a history of cardiac arrhythmias should use with caution; contraindicated in unstable conditions
Contraindicated concomitant use with monoamine oxidase inhibitors (MAOIs) if prescribed, due to potential interaction
Avoid use if concomitant severe hepatic or renal insufficiency is present without specialist consultation
Contraindicated in patients with known QT prolongation syndromes or concomitant drugs that prolong QT interval
Use contraindicated in patients with hypersensitivity to similar antihistamines including first-generation agents
Contraindicated in individuals with severe hypersensitivity reactions to any excipients used in oral formulations
Not recommended for off-label uses unsupported by safety data
Contraindicated use during lactation without medical advice restricting risk to newborn
Use in patients with uncontrolled cardiovascular or neurological disorders should be avoided
Administration is not appropriate in acute severe anaphylactic situations where immediate epinephrine administration is needed

Drug Interactions

Minimal clinically significant interactions due to limited cytochrome P450 involvement
Potential interaction with ketoconazole, erythromycin, and cimetidine which are CYP3A4 inhibitors, may increase loratadine plasma levels
No significant interaction noted with alcohol, though caution is advised due to potential additive sedative effects in sensitive individuals
Concurrent use with other sedating drugs could enhance CNS depression despite loratadine's low sedative profile
No major interaction with decongestants unless combined in fixed-dose formulations (e.g., loratadine-pseudoephedrine), which may raise blood pressure
No significant interaction with antacids or proton pump inhibitors affecting absorption
Loratadine metabolism may be altered by CYP2D6 inhibitors, though clinical effects are usually minimal
Potential interactions with herbal supplements such as St. John's Wort may alter loratadine plasma levels
No notable interaction with common analgesics or anti-inflammatory agents
Limited interaction potential with vitamins and mineral supplements
Caution advised when used with other QT-prolonging drugs due to theoretical risk of arrhythmias
No significant pharmacokinetic interactions with contraceptive medications
Monitoring advised when co-administering with strong CYP3A4 inhibitors in patients with hepatic impairment
Potential pharmacodynamic interactions with medications that cause dry mouth or CNS effects
Inform healthcare providers about all concurrent medications to avoid unanticipated adverse effects

Preparations Of The Drug

Oral capsules containing 10 mg loratadine
Oral syrup with concentration of 5 mg per 5 mL
Standard oral tablets available in 10 mg strength
Chewable oral tablets formulated as 5 mg tablets for pediatric use
Orally disintegrating tablets (ODT) available in 5 mg and 10 mg dosages
Combination products containing loratadine and pseudoephedrine for allergy and nasal congestion relief
Various branded products including Claritin, Alavert, Claritin Reditab, and Tavist ND
Generic loratadine formulations available in multiple dosage forms and strengths
Pediatric-specific formulations with dosing devices such as syringes for liquid preparations
Phenylalanine-containing chewable and ODT forms for non-PKU patients
Over-the-counter availability for multiple formulations facilitating ease of access
Manufactured under stringent quality controls conforming to pharmaceutical regulations
Packaged in blister packs for the disintegrating tablets to preserve stability
Available in unit-dose packaging facilitating outpatient use and compliance
Forms designed for ease of administration including options for patients with swallowing difficulties